The New York State Assembly has sent a bill to Governor Kathy Hochul that would change the labels on birth certificates from “mother” and “father” to “gestating parent” and “non‑gestating parent.” At the same time, the Biden administration is conducting a six‑month safety review of the abortion medication mifepristone under expanded telehealth rules, a move that has reignited partisan battles over reproductive rights.

Bill to Rename Parents Targets “Gestating” and “Non‑Gestating” Labels

The legislation, forwarded to Governor Hochul, seeks to reflect “the diverse family structures that exist today,” according to proponents who argue the change would reduce discrimination against transgender, non‑binary, and same‑sex couples.. By using the terms “gestating parent” and “non‑gestating parent,” the bill aims to separate biological function from parental identity.

Opponents warn that the new terminology could create confusion in legal documents and erode the historical understanding of parental roles . Critics also contend that the shift may complicate matters such as inheritance, custody, and vital statistics reporting.

Six‑Month Federal Review of Mifepristone Safety Under Telehealth Rules

The Biden administration reaffirmed its commitment to a comprehensive safety assessment of mifepristone, a medication whose in‑person screening requirement was lifted by the FDA in 2023. The review, projected to last about six months , will evaluate the drug’s safety when prescribed via telehealth and mailed to patients.

Reproductive‑rights groups hail the telehealth expansion as a major step toward broader access, while anti‑abortion advocates and some Republican lawmakers argue the review timeline is too short to produce meaningful findings before the upcoming elections.

Political Fallout: Senate Health Chair Calls for In‑Person Requirement

Senate Health Committee Chairman Senator Bill Cassidy (R‑LA) publicly urged the administration to reinstate the in‑person requirement, accusing officials of delaying action. He claims existing studies “underestimate serious complications,” a stance echoed by several anti‑abortion organizations.

According to the report, the FDA has responded by pledging a science‑based assessment and greater transparency, while the Guttmacher Institute continues to cite peer‑reviewed studies confirming the drug’s safety even when used remotely.

Unresolved Questions: Will the Review Influence Election‑Year Policy?

Two key uncertainties remain: whether the six‑month review will conclude before the November elections and how its findings might shape state‑level abortion legislation. The source notes that critics doubt the timeline will allow the results to affect voter sentiment, but no official deadline has been set.

Another open issue is how the birth‑certificate language change will be implemented across other states, many of which still use traditional gendered terms. As of now, no other jurisdiction has announced similar legislation.